Format

Send to

Choose Destination
See comment in PubMed Commons below
Dermatol Surg. 2012 Feb;38(2):199-206. doi: 10.1111/j.1524-4725.2011.02178.x. Epub 2011 Oct 10.

Treatment of melasma using a novel 1,927-nm fractional thulium fiber laser: a pilot study.

Author information

1
Department of Dermatology, University of Texas at Houston, Houston, Texas, USA. kristelpolder@hotmail.com

Abstract

BACKGROUND:

A 1,927-nm wavelength was recently added to the 1,550-nm erbium-doped fiber laser. This wavelength possesses a higher absorption coefficient for water than the 1,550-nm, conferring greater ability to target epidermal processes such as dyschromia.

OBJECTIVE:

To evaluate the efficacy and safety of a novel 1,927-nm fractional thulium fiber laser in the treatment of melasma.

METHODS:

Fourteen patients underwent three to four laser treatments (at 4-week intervals) at pulse energies of 10 to 20 mJ and total densities of 252 to 784 microscopic treatment zones per cm(2) (6-8 passes) using a 1,927-nm thulium fiber laser. Three blinded assessors and the patients evaluated clinical improvement of treatment areas at 1-, 3-, and 6-month follow-ups. Side effects were assessed, and pain was scored using a visual analog scale (0-10).

RESULTS:

A statistically significant 51% reduction in MASI score was observed at 1-month post 3 to 4 laser treatments. A 33% (p = .06) and 34% (p = .07) reduction in Melasma Area and Severity Index score was observed at the 3- and 6-month follow-up visits, respectively. Skin responses observed after treatment were moderate erythema and mild edema. No scarring or postinflammatory hyper- or hypopigmentation was observed.

CONCLUSION:

The 1,927-nm fractional thulium fiber laser is a safe, effective treatment for melasma.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center